Single Cell Sequencing Market

Single Cell Sequencing Market Overview

The single cell sequencing market is estimated to be worth $1,387 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period. Over the years, technological advances in the field of genomics have enabled pharma companies to adopt a more personalized and targeted approach to drug / therapy development. Specifically, next-generation sequencing (NGS) technologies have enabled millions of human genomes across diverse ethnicities, to be sequenced. The large volumes of blockchain in genomic data management from the aforementioned sequencing studies have led to the generation of valuable insights on individuals' likely responses to different treatment regimens. Innovation in this field have made NGS technologies increasingly affordable and accessible. In fact, the cost of sequencing a single genome has dropped from USD ~3 billion (Human Genome Project 1990) to USD 1,000 (Illumina sequencing kits) over the last two decades. However, NGS based analyses are limited to offering averaged insights on gene expression. In other words, this method is incapable of quantifying nucleic acid content in individual cells, and thereby, offering gene expression information at single cell resolution. To better understand the interactions of individual cells with their microenvironment, advanced molecular probing solutions are required. In this context, high-throughput single cell analysis, an emerging analytical technique, is considered a powerful means for studying individual cells, enabling researchers to study gene expression at single cell resolution.

Single cell technologies offer many advantages over traditional genomic analyses, enabling the detection of complex and rare cell populations, and elucidating development trajectories of distinct cell lineages. Despite the potential to be used across diverse segments in biotechnology and medical research, single cell technologies are still limited to early-stage research activities. This is primarily attributed to certain challenges associated with data processing and quality control. Further, the lack of versatile in silico tools is also considered among the major roadblocks to meaningful analysis and interpretation of single cell sequencing data. Additionally, the high cost of process execution and affiliated labor intensive protocols are other barriers to the adoption of since-cell sequencing technology.  However, the introduction of the RNA-QC-Chain tool in 2018 (an effort to address the data processing and quality control related challenges) and the Human Cell Atlas project (responsible for developing the first whole transcriptome map of human cells), are considered prominent milestones in the field of single cell genomics. Presently, experts believe that the single cell analysis market in North America, may reach USD 5 billion by 2025. Given, the potential of single-cell RNA sequencing (scRNA-seq) technologies to probe into previously unelucidated cellular mechanisms, and identify novel biomarkers / therapeutic targets, they are likely to witness significant market growth and adoption in biomedical research during the forecast period.

Key Companies in Single Cell Sequencing Market

Examples of key single cell companies engaged in single cell sequencing market (which have also been profiled in this market report; the complete list of single cell companies is available in the full report) include Active Motif, Admera Health, Annoroad Genomics, BGI Genomics, CD Genomics, MedGenome, Quick Biology, SingulOmics, 10x Genomics, Cell Microsystems, Fluidigm, Illumina, Mission Bio and Oxford Nanopore Technologies. This market report includes an easily searchable excel database of all the single cell companies, worldwide.

Recent Developments in Single Cell Sequencing Market:

Several recent developments have taken place in the field of single cell sequencing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In February 2026, ArgenTag secured strategic funding from IndieBio in order to accelerate adoption of its Single-Cell Long-Read sequencing platform, enabling detailed analysis of transcript isoforms and gene regulation at single-cell resolution for research in diseases and development.
• In February 2026, Complete Genomics get acquired by Swiss Rocket, enhancing capabilities in next-generation sequencing technologies including single-cell applications for genomic research and diagnostics.
• In January 2026, Daisy Genomics raised $2.5 million in seed funding in order to scale up its proprietary DNA and RNA sequencing platform using spectroscopy and chips for precision medicine.
• In February 2025, Illumina collaborated with Broad Clinical Labs on end-to-end single-cell workflows and CRISPR Perturb-seq to build a 5 billion single-cell atlas ecosystem over three years, accelerating drug discovery efforts. 

Scope of the Report

The ‘Single Cell Sequencing Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the single cell sequencing market.

In addition to other elements, the market research report features:

• An overview of the competitive landscape of single-cell sequencing service providers providing information on a number of parameters, such as year of establishment, company size, geographical location, sequencing method used (DNA sequencing, RNA sequencing, ATAC sequencing and DNA methylation), types of services offered (library preparation, sequencing and bioinformatics), type of library preparation system used and type of sequencing system used. 
• A detailed review of the competitive market landscape of single-cell sequencing workflow instruments providing information on a number of relevant parameters, such as target nucleic acid (DNA, RNA and protein), type of application (cell isolation, cDNA amplification and library preparation) and throughput. In addition, the report features competitive market landscape of single-cell sequencing systems providing information on parameters, such as type of application (single-cell, whole genome, whole exome and targeted sequencing), maximum output, maximum read length, system efficiency, sequencing chemistry (sequencing-by-synthesis, SMRT sequencing and nanopore sequencing). It also includes an analysis on the single cell companies developing these systems, based on year of establishment, company size and geographical location.
• An insightful competitiveness analysis of single cell technologies based on relevant parameters, such as supplier power (based on a company’s employee count and years of experience) and other important technology related specifications, such as maximum sequencing output, maximum reads per run, maximum read length, quality score, applications and cost of sequencer.
• Elaborate profiles of single cell companies that are engaged in offering single-cell sequencing services and single cell technologies. Each profile features a brief overview of the company, its financial information (if available), proprietary technology platform(s), recent developments and an informed future outlook.
• An in-depth analysis of the various patents that have been filed / granted for single-cell sequencing technologies, based on parameters, such as patent type, publication year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus areas, and type of applicant, highlighting the leading industry / non-industry players (in terms of the size of intellectual property portfolio). It also features a patent benchmarking and valuation analysis.
• A detailed analysis of the grants that have been awarded to research institutes engaged in projects related to single-cell sequencing, between 2016 and 2020, based on multiple parameters, such as year of grant award, grant amount, focus area, activity code, support period, funding mechanism, funding institute center, type of recipient organization, popular recipient organizations and prominent program officers. 
• An analysis of various developments / recent trends related to single-cell sequencing, offering insights on [A] partnerships and collaborations established within the industry, [B] funding and investments, and [C] recent product launches related to single-cell sequencing.

The key objective of single cell sequencing market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for single cell analysis market during the forecast period. Based on several parameters, such as number of single-cell samples sequenced annually, average cost of sequencing, and growth trends across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the forecast period 2020-2030. The chapter features the likely distribution of the opportunity across different [A] key market segments (services and technologies), [B] type of system (sequencing and workflow instruments), [C] end-user (pharmaceutical companies, academic and research institutions and other end-users), [D] area of application (diagnostics, drug discovery, precision medicine and others) and [E] geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this market research report were influenced by discussions conducted with multiple stakeholders in single cell sequencing market.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.